Literature DB >> 30714830

The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.

Andreas M Hötker1, Evelyn Dappa2, Yousef Mazaheri3, Behfar Ehdaie4,5, Junting Zheng5, Marinela Capanu5, Hedvig Hricak6, Oguz Akin6.   

Abstract

OBJECTIVE: The objective of this study was to develop a scoring system for background signal intensity changes or prostate homogeneity on prostate MRI and to assess these changes' influence on cancer detection.
MATERIALS AND METHODS: This institutional review board-approved, HIPAA-compliant, retrospective study included 418 prostate MRI examinations in 385 men who subsequently underwent MRI-guided biopsy. The Likert score for suspicion of cancer assigned by the primary radiologist was extracted from the original report, and histopathologic work-up of the biopsy cores served as the reference standard. Two readers assessed the amount of changes on T2-weighted sequences and assigned a predefined prostate signal-intensity homogeneity score of 1-5 (1 = poor, extensive changes; 5 = excellent, no changes). The sensitivity and specificity of Likert scores for detection of prostate cancer and clinically significant cancer (Gleason score ≥ 3+4) were estimated in and compared between subgroups of patients with different signal-intensity homogeneity scores (≤ 2, 3, and ≥ 4).
RESULTS: Interreader agreement on signal-intensity homogeneity scores was substantial (κ = 0.783). Sensitivity for prostate cancer detection increased when scores were better (i.e., higher) (reader 1, from 0.41 to 0.71; reader 2, from 0.53 to 0.73; p ≤ 0.007, both readers). In the detection of significant cancer (Gleason score ≥ 3+4), sensitivity also increased with higher signal-intensity scores (reader 1, from 0.50 to 0.82; reader 2, from 0.63 to 0.86; p ≤ 0.028), though specificity decreased significantly for one reader (from 0.67 to 0.38; p = 0.009).
CONCLUSION: Background signal-intensity changes on T2-weighted images significantly limit prostate cancer detection. The proposed scoring system could improve the standardization of prostate MRI reporting and provide guidance for applying prostate MRI results appropriately in clinical decision-making.

Entities:  

Keywords:  MRI; prostate cancer

Mesh:

Year:  2019        PMID: 30714830      PMCID: PMC6430663          DOI: 10.2214/AJR.18.20295

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

Review 1.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

2.  The effects of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer.

Authors:  Kyung Kgi Park; Seung Hwan Lee; Beom Jin Lim; Joo Hee Kim; Byung Ha Chung
Journal:  BJU Int       Date:  2010-10       Impact factor: 5.588

3.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

Authors:  Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma
Journal:  Eur Urol       Date:  2015-10-01       Impact factor: 20.096

Review 4.  Mammographic breast density: impact on breast cancer risk and implications for screening.

Authors:  Phoebe E Freer
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

5.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Akira Yamamoto; Takenori Yamashita; Naoto Egashira; Shigeki Imai; Masao Fukunaga
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

6.  Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography.

Authors:  Patricia A Carney; Diana L Miglioretti; Bonnie C Yankaskas; Karla Kerlikowske; Robert Rosenberg; Carolyn M Rutter; Berta M Geller; Linn A Abraham; Steven H Taplin; Mark Dignan; Gary Cutter; Rachel Ballard-Barbash
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

7.  Impact of delay after biopsy and post-biopsy haemorrhage on prostate cancer tumour detection using multi-parametric MRI: a multi-reader study.

Authors:  A B Rosenkrantz; T C Mussi; N Hindman; R P Lim; M X Kong; J S Babb; J Melamed; S S Taneja
Journal:  Clin Radiol       Date:  2012-09-13       Impact factor: 2.350

8.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images.

Authors:  S White; H Hricak; R Forstner; J Kurhanewicz; D B Vigneron; C J Zaloudek; J M Weiss; P Narayan; P R Carroll
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

Review 9.  Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions.

Authors:  Yi Li; John Mongan; Spencer C Behr; Seema Sud; Fergus V Coakley; Jeffry Simko; Antonio C Westphalen
Journal:  Radiographics       Date:  2016-06-17       Impact factor: 5.333

10.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

View more
  2 in total

Review 1.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 2.  [PI-RADS 2.1 and structured reporting of magnetic resonance imaging of the prostate].

Authors:  Andreas Hötker; Olivio F Donati
Journal:  Radiologe       Date:  2021-07-02       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.